These data suggest that promoting ACVR1C through exercise or pharmacological intervention may protect against age and AD-associated cognitive impairment, providing a powerful and druggable target as a potential disease modifying treatment strategy for AD. Here, ACVR1C is linked to Cognitive impairment.